000 05601cam a2200445Mi 4500
988 _aSpringer_Medicine_2017
999 _c96396
_d96396
_x1
001 96396
003 ES-MaUEC
005 20230118121148.0
006 m o d
007 cr cnu---unuuu
008 170805s2017 xx o 000 0 eng d
020 _a3319561146
_q(electronic bk.)
020 _a9783319561141
_q(electronic bk.)
020 _z3319561138
020 _z9783319561134
040 _aEBLCP
_cEBLCP
_dN$T
_dYDX
_dGW5XE
_dDKU
_dOCLCF
_dUAB
_dAZU
_dOCLCQ
_dUPM
_dMERER
_dOCLCQ
_dESU
_dIOG
_dCOO
_dOCLCA
_dES-MaUEC
_bspa
050 4 _aRC280.U74
_b2017 EB
245 0 0 _aPrinciples and Practice of Urooncology :
_bRadiotherapy, Surgery and Systemic Therapy
_cGokhan Ozyigit, Ugur Selek, editors.
264 1 _aCham
_bSpringer
_c2017.
300 _a1 recurso en línea (447 páginas)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
500 _aSpringerLink
504 _aIncluye referencias bibliográficas
505 0 _aPreface; Acknowledgments; Contents; List of Contributors; 1: Radiological Imaging in Urological Cancers; 1.1 Introduction; 1.2 Renal Cancer; 1.2.1 General Information; 1.2.2 Imaging Techniques; 1.2.2.1 Ultrasonography; 1.2.2.2 Computed Tomography; 1.2.2.3 Magnetic Resonance Imaging; Malignant Tumors of Renal Pelvis; Metastases; Lymphoma; Primary Renal Mesenchymal Tumors; 1.2.3 Staging of Renal Tumors; 1.2.4 Intervention in Renal Masses; 1.3 Bladder Cancer; 1.3.1 General Information; 1.3.2 Imaging Features; 1.3.2.1 Ultrasonography; 1.3.2.2 Computed Tomography.
505 8 _a1.3.2.3 Magnetic Resonance Imaging1.3.3 Staging; 1.3.3.1 Lymph Node Metastasis; 1.3.3.2 Metastasis Staging; 1.3.4 Monitoring After Treatment; 1.4 Prostate Cancer; 1.4.1 General Information; 1.4.2 Imaging Features; 1.4.2.1 Ultrasonography; 1.4.2.2 Computed Tomography; 1.4.2.3 Magnetic Resonance Imaging; 1.4.3 Local Staging of Patients with Biopsy-Proven Prostate Cancer; 1.4.3.1 Lymph Node Metastasis; 1.4.3.2 Distant Metastasis; 1.4.3.3 Preprocedural Assessment; 1.4.3.4 Metabolic Imaging; 1.4.3.5 Evaluation of Recurrence; References.
505 8 _a2.10 Surgical Management of Muscle-Invasive Bladder CancerReferences; 3: Target Volume Delineation Guidelines in Bladder Cancer; 3.1 Anatomy; 3.2 Role of Radiotherapy for Locoregional Disease; 3.3 Target Volume Delineation; 3.4 Definitive Radiotherapy for the Intact Bladder; 3.4.1 Gross Tumor Volume; 3.4.2 Clinical Target Volume; 3.4.3 Role of Elective Nodal Irradiation; 3.4.4 Planning Target Volume; 3.5 Adjuvant Setting; References; 4: Bladder Preservation Therapies in Bladder Cancer; 4.1 Introduction; 4.2 Management of Non-muscle-Invasive Bladder Cancer.
505 8 _a2: Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers2.1 Introduction; 2.2 Management of Non-muscle-Invasive Bladder Cancer; 2.3 Repeat/Restaging Transurethral Resection; 2.4 Intravesical Chemotherapy; 2.5 Intravesical Immunotherapy; 2.6 Treatment Alternatives During the Global Shortage of BCG; 2.6.1 Alternative BCG Schedules; 2.6.2 Alternative Intravesical Chemotherapy Applications; 2.7 Future Perspectives; 2.8 Treatment of Disease Unresponsive to or Relapsing After BCG Vaccination; 2.9 Upfront Cystectomy for Very High-Risk NMIBC.
505 8 _a4.3 Treatment of Muscle-Invasive Disease4.3.1 Monotherapy; 4.3.2 Multimodal Approach; 4.4 Metastatic Disease and Recurrences; 4.5 Irradiation Techniques; 4.5.1 Simulation, Target Volume, and Fields; 4.5.2 Tumor Localization; 4.5.3 Target Delineation; 4.5.4 Doses and RT Schedules; 4.5.5 IMRT and IGRT; 4.5.6 Brachytherapy; References; 5: Systemic Therapy for Bladder Cancer; 5.1 Introduction; 5.2 Systemic Therapies in Muscle-Invasive Bladder Cancer; 5.3 Treatment of Advanced and Metastatic Disease; 5.3.1 DNA-Targeted Chemotherapy; 5.3.2 Targeted Therapies; 5.3.3 Immunotherapy.
520 3 _aThis evidence-based, state of the art guide to the management of urological malignancies, including bladder cancer, prostate cancer, and testicular cancer, is designed to serve as an easy-to-consult reference that will assist in daily decision making and the delivery of optimal care for individual patients within a multidisciplinary setting. Readers will find up-to-date information on patient selection and the full range of treatment modalities, including modern radiotherapy techniques, systemic chemotherapy, surgical procedures (including robotic surgery and other minimally invasive approaches), hormonal therapies, immunotherapy, and focal therapies. With regard to radiotherapy, the coverage encompasses everything from delineation of tumor volumes and organs at risk based on CT simulation through to delivery of stereotactic body radiotherapy, intensity-modulated radiation therapy, tomotherapy, volumetric modulated arc therapy, and proton therapy. The authors are leading authorities with international reputations who have been selected for their expertise in the topic that they address. The book will be of value for all practicing urooncologists as well as other oncology fellows and residents interested in urooncology.
650 7 _aAparato urinario
_xCáncer
_2embne
_9224160
700 1 _aOzyigit, Gokhan
_994971
700 1 _aSelek, Ugur.
_994972
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-56114-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI